TXMD TherapeuticsMD
- 2.195
- +0.075+3.54%
TherapeuticsMD News
TherapeuticsMD | ARS: Annual Report to Security Holders
TherapeuticsMD | SC 14D9/A: Tender offer solicitation/recommendation statements filed under Rule 14d-9 (Amendment)
TherapeuticsMD | SC TO-T/A: Third party tender offer statement (Amendment)
TherapeuticsMD | SC 14D9/A: Tender offer solicitation/recommendation statements filed under Rule 14d-9 (Amendment)
TherapeuticsMD | SC TO-T/A: Third party tender offer statement (Amendment)
TherapeuticsMD | SC 14D9/A: Tender offer solicitation/recommendation statements filed under Rule 14d-9 (Amendment)
TherapeuticsMD | SC TO-T/A: Third party tender offer statement (Amendment)
TherapeuticsMD | SC 14D9: Tender offer solicitation/recommendation statements filed under Rule 14d-9
TherapeuticsMD | SC TO-T: Third party tender offer statement
TherapeuticsMD | SC TO-C: Written communication relating to an issuer or third party tender offer
TherapeuticsMD | SC14D9C: Written communication by the subject company relating to a third party tender offer
TherapeuticsMD | POSASR: Post-effective amendment to an automatic shelf registration statement on Form S-3ASR or Form F-3ASR
TherapeuticsMD | SC TO-I/A: Issuer tender offer statement (Amendment)
TherapeuticsMD | SC TO-I/A: Issuer tender offer statement (Amendment)
TherapeuticsMD | SC TO-I: Issuer tender offer statement
TherapeuticsMD | SEC STAFF LETTER: Others
TherapeuticsMD | SEC STAFF LETTER: Others
TherapeuticsMD | PRER14A: Preliminary revised proxy soliciting materials
TherapeuticsMD | SEC STAFF LETTER: Others
TherapeuticsMD | POSASR: Post-effective amendment to an automatic shelf registration statement on Form S-3ASR or Form F-3ASR
Analysis
Price Target
No Data
